Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 82

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 82
---
 are key to retaining key talent to drive our business forward.The Board believes that equity awards are a key element underlying our ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully, through this time of transition for our Company, and implement our business plan to develop our pipeline of therapeutics. Equity awards align the interests of our key personnel with those of our stockholders and are a substantial contributing factor to our success and the future growth of our business. |

| • | Current shares available for awards are inadequate.We believe that the shares currently available for grant under the 2020 Plan will be insufficient to meet our anticipated retention and recruiting needs. As of June 18, 2025, there were 47,409 shares available for future grant under the 2020 Plan. |

Information regarding Equity Incentive Program, Dilution and Overhang The following table provides certain information regarding our equity incentive program:

|                                                                                                       |     |      As of 
   June 18, 
       2025 |
|:------------------------------------------------------------------------------------------------------|:----|-----------:|
| Total number of shares of Common Stock subject to outstanding stock options                           |     | $1,230,272 |
| Weighted-average exercise price of outstanding stock options                                          |     |      $3.79 |
| Weighted-average remaining term of outstanding stock options                                          |     | 9.16 years |
| Total number of shares of Common Stock subject to outstanding full value awards                       |     |          0 |
| Total number of shares of Common Stock available for grant under the 2020 Plan                        |     |     47,409 |
| Total number of shares of Common Stock available for grant under the 2015 New Employee Incentive Plan |     |     76,025 |
| Total number of shares of Common Stock outstanding                                                    |     | 60,490,101 |
| Per-share closing price of Common Stock as reported on the Nasdaq Capital Market                      |     |      $0.20 |

To provide the Company the flexibility to responsibly address our future equity compensation needs, we are requesting that stockholders approve the Fifth Amended Plan to make an additional 20,000,000 shares available for grant. Grant levels for the preceding three (3) fiscal years have averaged 191,805 shares per year.

51

TABLE OF CONTENTS

The following table shows our key dilution metrics over the last three years:

| Key Equity Metrics      |     | Three-Year 
 Average    |     |